Pivotal CMT1A Trial to Begin Patient Enrollment Soon

Pivotal CMT1A Trial to Begin Patient Enrollment Soon

285464

Pivotal CMT1A Trial to Begin Patient Enrollment Soon

An international Phase 3 clinical trial investigating Pharnext‘s investigational therapy PXT3003 for treating Charcot-Marie-Tooth disease type 1A (CMT1A) is on track and expected to enroll its first participants in March, the company announced. Dubbed PREMIER, the trial will include about 350 patients with mild-to-moderate CMT1A across 50 clinical sites. Findings are expected to support the filing of an application with the U.S. Food and Drug Administration  (FDA) requesting the approval of PXT3003 for this disease subtype. Meanwhile, the company is…

You must be logged in to read/download the full post.